Merus (NASDAQ:MRUS) Receives $56.33 Average Price Target from Analysts

Merus (NASDAQ:MRUS) has received a consensus rating of “Buy” from the eleven ratings firms that are currently covering the firm, MarketBeat.com reports. Eleven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $56.33.

A number of brokerages recently issued reports on MRUS. Truist Financial began coverage on Merus in a research report on Thursday, March 28th. They issued a “buy” rating and a $69.00 target price for the company. BMO Capital Markets upped their target price on Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday, February 29th. William Blair reissued an “outperform” rating on shares of Merus in a research report on Monday, April 22nd. HC Wainwright upped their target price on Merus from $48.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. Finally, Stifel Nicolaus upped their price objective on Merus from $40.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, February 29th.

Merus Stock Performance

NASDAQ:MRUS opened at $45.04 on Monday. The stock has a 50-day simple moving average of $45.05 and a 200-day simple moving average of $33.66. The stock has a market cap of $2.64 billion, a P/E ratio of -14.78 and a beta of 1.10. Merus has a 1 year low of $18.21 and a 1 year high of $52.03.

Merus (NASDAQ:MRUS) last announced its earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.38). The firm had revenue of $8.94 million during the quarter, compared to analyst estimates of $10.43 million. Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. On average, equities research analysts predict that Merus will post -3.29 EPS for the current year.

Hedge Funds Weigh In On Merus

Large investors have recently modified their holdings of the business. BluePath Capital Management LLC purchased a new position in shares of Merus during the 3rd quarter worth approximately $33,000. Quadrant Capital Group LLC raised its stake in shares of Merus by 37.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after buying an additional 343 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Merus by 142.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after buying an additional 867 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Merus by 64.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock worth $58,000 after buying an additional 828 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of Merus during the 1st quarter worth approximately $72,000. 96.14% of the stock is owned by hedge funds and other institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.